Abbott India Limited
Abbott India Limited, together with its subsidiaries, operates as a pharmaceutical company in India. The company offers pharmaceutical products for gastroenterology, women's health, metabolic, central nervous system, vaccines, and multispecialty, including insomnia, vitamin D deficiency, pre-term labor, and pain management. It also provides anti-infectives, cardio-diabeto, GI & hepato, hormones, … Read more
Abbott India Limited (ABBOTINDIA) - Net Assets
Latest net assets as of September 2025: ₹40.11 Billion INR
Based on the latest financial reports, Abbott India Limited (ABBOTINDIA) has net assets worth ₹40.11 Billion INR as of September 2025.
Net assets (also known as shareholders' equity or book value) represent the difference between a company's total assets (₹56.94 Billion) and total liabilities (₹16.84 Billion). This figure indicates the residual interest in the assets after deducting liabilities, essentially showing what would remain for shareholders if all assets were liquidated and all debts paid off.
Key Net Assets Metrics
| Metric | Value |
|---|---|
| Current Net Assets | ₹40.11 Billion |
| % of Total Assets | 70.44% |
| Annual Growth Rate | 16.84% |
| 5-Year Change | 62.68% |
| 10-Year Change | 254.06% |
| Growth Volatility | 16.27 |
Abbott India Limited - Net Assets Trend (2005–2025)
This chart illustrates how Abbott India Limited's net assets have evolved over time, based on quarterly financial data. Explore and compare other companies by net assets.
Annual Net Assets for Abbott India Limited (2005–2025)
The table below shows the annual net assets of Abbott India Limited from 2005 to 2025.
| Year | Net Assets | Change |
|---|---|---|
| 2025-03-31 | ₹42.33 Billion | +14.44% |
| 2024-03-31 | ₹36.99 Billion | +16.01% |
| 2023-03-31 | ₹31.89 Billion | +13.08% |
| 2022-03-31 | ₹28.20 Billion | +8.36% |
| 2021-03-31 | ₹26.02 Billion | +7.01% |
| 2020-03-31 | ₹24.32 Billion | +21.07% |
| 2019-03-31 | ₹20.09 Billion | +18.66% |
| 2018-03-31 | ₹16.93 Billion | +22.05% |
| 2017-03-31 | ₹13.87 Billion | +16.00% |
| 2016-03-31 | ₹11.96 Billion | +27.53% |
| 2015-03-31 | ₹9.38 Billion | +12.54% |
| 2014-03-31 | ₹8.33 Billion | +28.79% |
| 2013-03-31 | ₹6.47 Billion | +18.88% |
| 2012-03-31 | ₹5.44 Billion | +78.18% |
| 2011-03-31 | ₹3.05 Billion | +12.46% |
| 2010-03-31 | ₹2.72 Billion | +22.74% |
| 2009-03-31 | ₹2.21 Billion | -4.24% |
| 2008-03-31 | ₹2.31 Billion | -6.02% |
| 2007-03-31 | ₹2.46 Billion | +13.57% |
| 2006-03-31 | ₹2.16 Billion | +14.96% |
| 2005-03-31 | ₹1.88 Billion | -- |
Equity Component Analysis
This analysis shows how different components contribute to Abbott India Limited's total equity over time. Equity components include common stock, retained earnings, additional paid-in capital, and other elements.
Equity Composition Insights
- Retained earnings have grown by 2143.4% over the analyzed period, indicating profitable operations and earnings retention.
Current Equity Component Breakdown (March 2025)
| Component | Amount | Percentage |
|---|---|---|
| Retained Earnings | ₹32.21 Billion | 76.08% |
| Common Stock | ₹212.50 Million | 0.50% |
| Other Components | ₹9.91 Billion | 23.41% |
| Total Equity | ₹42.33 Billion | 100.00% |
Abbott India Limited Competitors by Market Cap
The table below lists competitors of Abbott India Limited ranked by their market capitalization.
| Company | Market Cap |
|---|---|
|
Scatec Solar OL
OL:SCATC
|
$1.59 Billion |
|
Veritex Holdings Inc
NASDAQ:VBTX
|
$1.59 Billion |
|
Zhejiang Dingli Mach Co Ltd
SHG:603338
|
$1.59 Billion |
|
Dalmia Bharat Limited
NSE:DALBHARAT
|
$1.59 Billion |
|
Douglas Emmett Inc
NYSE:DEI
|
$1.59 Billion |
|
Hillman Solutions Corp
NASDAQ:HLMN
|
$1.59 Billion |
|
Tasly Pharmaceutical Group Co Ltd
SHG:600535
|
$1.58 Billion |
|
Deutz AG
XETRA:DEZ
|
$1.58 Billion |
Equity Growth Attribution
This analysis shows how different factors contributed to changes in Abbott India Limited's equity between the two most recent reporting periods.
Equity Growth Insights
- From 2024 to 2025, total equity changed from 36,988,900,000 to 42,331,500,000, a change of 5,342,600,000 (14.4%).
- Net income of 14,144,400,000 contributed positively to equity growth.
- Dividend payments of 8,712,200,000 reduced retained earnings.
- Other comprehensive income decreased equity by 451,000,000.
Equity Change Factors (2024 to 2025)
| Factor | Impact | Contribution |
|---|---|---|
| Net Income | ₹14.14 Billion | +33.41% |
| Dividends Paid | ₹8.71 Billion | -20.58% |
| Other Comprehensive Income | ₹-451.00 Million | -1.07% |
| Other Changes | ₹361.40 Million | +0.85% |
| Total Change | ₹- | 14.44% |
Book Value vs Market Value Analysis
This analysis compares Abbott India Limited's book value (net assets) with its market value over time. The relationship between these values can provide insights into investor sentiment and company valuation.
Valuation Insights
- Current price-to-book ratio: 13.28x
- The company is trading at a significant premium to its book value, suggesting the market values its earnings potential, brand, or other intangibles highly.
- The price-to-book ratio has decreased from 214.66x to 13.28x over the analyzed period, indicating reduced market premium.
Historical Price-to-Book Ratios
| Date | Book Value per Share | Market Price | P/B Ratio |
|---|---|---|---|
| 2005-03-31 | ₹123.22 | ₹26450.00 | x |
| 2006-03-31 | ₹141.65 | ₹26450.00 | x |
| 2007-03-31 | ₹160.87 | ₹26450.00 | x |
| 2008-03-31 | ₹155.32 | ₹26450.00 | x |
| 2009-03-31 | ₹153.51 | ₹26450.00 | x |
| 2010-03-31 | ₹198.58 | ₹26450.00 | x |
| 2011-03-31 | ₹223.31 | ₹26450.00 | x |
| 2012-03-31 | ₹256.08 | ₹26450.00 | x |
| 2013-03-31 | ₹304.41 | ₹26450.00 | x |
| 2014-03-31 | ₹370.77 | ₹26450.00 | x |
| 2015-03-31 | ₹441.20 | ₹26450.00 | x |
| 2016-03-31 | ₹562.65 | ₹26450.00 | x |
| 2017-03-31 | ₹652.70 | ₹26450.00 | x |
| 2018-03-31 | ₹796.62 | ₹26450.00 | x |
| 2019-03-31 | ₹945.25 | ₹26450.00 | x |
| 2020-03-31 | ₹1144.39 | ₹26450.00 | x |
| 2021-03-31 | ₹1224.59 | ₹26450.00 | x |
| 2022-03-31 | ₹1327.00 | ₹26450.00 | x |
| 2023-03-31 | ₹1500.56 | ₹26450.00 | x |
| 2024-03-31 | ₹1740.74 | ₹26450.00 | x |
| 2025-03-31 | ₹1992.07 | ₹26450.00 | x |
Capital Efficiency Dashboard
This dashboard shows how efficiently Abbott India Limited utilizes its equity to generate returns, including Return on Equity (ROE) and its components based on the DuPont analysis framework.
Capital Efficiency Insights
- Current Return on Equity (ROE): 33.41%
- The company demonstrates strong efficiency in generating profits from shareholder equity.
- DuPont Analysis Breakdown:
- • Net Profit Margin: 22.07%
- • Asset Turnover: 1.08x
- • Equity Multiplier: 1.40x
- Recent ROE (33.41%) is above the historical average (26.90%), indicating improving capital efficiency.
Historical Capital Efficiency Metrics
| Year | Return on Equity | Net Profit Margin | Asset Turnover | Equity Multiplier | Economic Value Added |
|---|---|---|---|---|---|
| 2005 | 54.31% | 25.24% | 1.30x | 1.66x | ₹834.22 Million |
| 2006 | 27.33% | 13.30% | 1.43x | 1.43x | ₹375.16 Million |
| 2007 | 24.35% | 11.73% | 1.50x | 1.39x | ₹352.79 Million |
| 2008 | 29.62% | 11.51% | 1.80x | 1.43x | ₹453.28 Million |
| 2009 | 28.42% | 9.44% | 1.90x | 1.58x | ₹407.46 Million |
| 2010 | 28.54% | 10.19% | 1.96x | 1.43x | ₹503.55 Million |
| 2011 | 19.95% | 6.16% | 2.16x | 1.50x | ₹303.97 Million |
| 2012 | 22.13% | 8.34% | 1.80x | 1.47x | ₹659.79 Million |
| 2013 | 22.37% | 8.99% | 1.77x | 1.40x | ₹800.15 Million |
| 2014 | 21.17% | 8.92% | 1.64x | 1.45x | ₹879.66 Million |
| 2015 | 24.42% | 10.24% | 1.63x | 1.47x | ₹1.35 Billion |
| 2016 | 21.35% | 9.90% | 1.59x | 1.35x | ₹1.36 Billion |
| 2017 | 19.95% | 9.56% | 1.40x | 1.49x | ₹1.38 Billion |
| 2018 | 23.70% | 12.16% | 1.37x | 1.43x | ₹2.32 Billion |
| 2019 | 22.42% | 12.25% | 1.25x | 1.46x | ₹2.49 Billion |
| 2020 | 24.38% | 14.49% | 1.15x | 1.46x | ₹3.50 Billion |
| 2021 | 26.54% | 16.03% | 1.12x | 1.48x | ₹4.30 Billion |
| 2022 | 28.32% | 16.27% | 1.16x | 1.50x | ₹5.17 Billion |
| 2023 | 29.78% | 17.76% | 1.17x | 1.43x | ₹6.31 Billion |
| 2024 | 32.48% | 20.54% | 1.13x | 1.40x | ₹8.31 Billion |
| 2025 | 33.41% | 22.07% | 1.08x | 1.40x | ₹9.91 Billion |
Industry Comparison
This section compares Abbott India Limited's net assets metrics with peer companies in the Drug Manufacturers - Specialty & Generic industry.
Industry Context
- Industry: Drug Manufacturers - Specialty & Generic
- Average net assets among peers: $9,124,464,358
- Average return on equity (ROE) among peers: 12.58%
Peer Company Comparison
| Company | Net Assets | Return on Equity | Debt-to-Equity | Market Cap |
|---|---|---|---|---|
| Abbott India Limited (ABBOTINDIA) | ₹40.11 Billion | 54.31% | 0.42x | $1.59 Billion |
| Aarey Drugs & Pharmaceuticals Limited (AAREYDRUGS) | $802.45 Million | 7.70% | 1.12x | $11.20 Million |
| Aarti Drugs Limited (AARTIDRUGS) | $1.12 Billion | 12.32% | 2.74x | $149.72 Million |
| Ajanta Pharma Limited (AJANTPHARM) | $15.68 Billion | 32.33% | 0.16x | $1.46 Billion |
| Akums Drugs and Pharmaceutical (AKUMS) | $7.20 Billion | -0.56% | 3.88x | $123.83 Million |
| Albert David Limited (ALBERTDAVD) | $2.44 Billion | 9.06% | 0.40x | $15.85 Million |
| Alivus Life Sciences Limited (ALIVUS) | $28.17 Billion | 17.24% | 0.21x | $333.13 Million |
| Alkem Laboratories Limited (ALKEM) | $23.74 Billion | 20.90% | 0.71x | $2.41 Billion |
| Alpa Laboratories Limited (ALPA) | $56.73 Million | 0.53% | 2.47x | $5.55 Million |
| Amrutanjan Health Care Limited (AMRUTANJAN) | $2.91 Billion | 13.70% | 0.25x | $77.60 Million |